Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

Data from a retrospective study of results from two multicenter cohort trials—X-TREME and Study 240—showed variations in initiation, implementation, and persistence of denosumab use among adult patients with bone metastases from primary breast, prostate, lung, kidney, or other solid cancer types. Most patients experienced timely initiation (64.4% to 81.2%) and optimal implementation (62.4% to 72.5%), while 41.4% to 77.8% of patients were persistent with treatment at 6 months.